Showing posts with label drug. Show all posts
Showing posts with label drug. Show all posts
Saturday, 13 February 2016
Lymphoma drug may help in fight against Alzheimer's
Alzheimer's preventative drug hope - http://www.bbc.co.uk/news/health-35558438
Wednesday, 7 October 2015
Mansfield boy given Life saving Leukaemia drug
http://www.mirror.co.uk/news/uk-news/leukaemia-wonder-drug-cures-british-6576878
Monday, 3 October 2011
Breakthrough in Mixed Lineage Leukaemia (MLL) Drug Search
.
British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukaemia(MLL) - the most common form of leukaemia in babies.
In a study published in the journal Nature, scientists from the British drug maker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukaemia genes.
To read the full story click HERE.
.
British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukaemia(MLL) - the most common form of leukaemia in babies.
In a study published in the journal Nature, scientists from the British drug maker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukaemia genes.
To read the full story click HERE.
.
Wednesday, 17 March 2010
New cancer treatment gives hope to lymphoma and leukaemia patients
Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukaemia.
PCI-32765 is a new drug being assessed in a Phase I clinical trial at the Virginia G. Piper Cancer Centre in collaboration with the Clinical Division of the Translational Genomics Research Institute (TGen).
This is one of 35 such trials under way through a partnership between the Virginia G. Piper Cancer Centre at Scottsdale Healthcare and TGen, which enables molecular and genomic discoveries to reach patients through Phase I trials as quickly as possible.
'Progress in developing new treatments for cancer has been painfully slow as only 2-4 percent of all cancer patients enroll in clinical trials. This is especially true for uncommon cancers such as leukaemia's and lymphomas,' said Dr Raoul Tibes, Director of the Haematological Malignancies Program at the Virginia G. Piper Cancer Centre and an Associate Investigator at TGen.
Clinical trials test the safety and effectiveness of new drugs prior to approval by the U.S. Food and Drug Administration. Participants are volunteers for whom other cancer treatments have failed. Arizona is one of many states in which clinical trials often are covered by health insurance.
'This study is going very well. It is a very promising agent,'' Dr Tibes said of PCI-32765, which uniquely targets the molecular abnormalities of lymphoma cells. 'This is a recently identified cancer mechanism that we are going after with this drug in lymphoma cells.'
To Read more about this news click HERE to visit the Science Centric Webpage.
.
PCI-32765 is a new drug being assessed in a Phase I clinical trial at the Virginia G. Piper Cancer Centre in collaboration with the Clinical Division of the Translational Genomics Research Institute (TGen).
This is one of 35 such trials under way through a partnership between the Virginia G. Piper Cancer Centre at Scottsdale Healthcare and TGen, which enables molecular and genomic discoveries to reach patients through Phase I trials as quickly as possible.
'Progress in developing new treatments for cancer has been painfully slow as only 2-4 percent of all cancer patients enroll in clinical trials. This is especially true for uncommon cancers such as leukaemia's and lymphomas,' said Dr Raoul Tibes, Director of the Haematological Malignancies Program at the Virginia G. Piper Cancer Centre and an Associate Investigator at TGen.
Clinical trials test the safety and effectiveness of new drugs prior to approval by the U.S. Food and Drug Administration. Participants are volunteers for whom other cancer treatments have failed. Arizona is one of many states in which clinical trials often are covered by health insurance.
'This study is going very well. It is a very promising agent,'' Dr Tibes said of PCI-32765, which uniquely targets the molecular abnormalities of lymphoma cells. 'This is a recently identified cancer mechanism that we are going after with this drug in lymphoma cells.'
To Read more about this news click HERE to visit the Science Centric Webpage.
.
Subscribe to:
Posts (Atom)